GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Parmax Pharma Ltd

Parmax Pharma Board Approves Shifting Registered Office to Maharashtra

BOARD ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 14 Nov 2026, 09:44 PM IST  ·  BSE ID: 41f34d18-75e1-4fb3-a2b6-1f29f53f2bcb
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's directors approved moving its official address to another state and boosting borrowing power.
🤖 AI Summary
  • Board approved shifting registered office to Maharashtra, pending shareholder and regulatory consent.
  • Approved enhancing limits for asset sale/mortgage and borrowing to Rs. 50 crores each.
  • Shareholder approval is required for registered office shift and limit enhancements.
  • Consideration of un-audited financial results for Q2 FY27 was adjourned.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Enhanced asset sale/mortgage limit
Rs. 50 crores
Enhanced borrowing limit
Rs. 50 crores
🏢 How This Affects the Company
📈
Business Impact
Shifting the registered office to Maharashtra could align with strategic operational or market presence goals. Enhanced borrowing and asset limits provide flexibility for future expansion or acquisitions.
💰
Financial Impact
Increased borrowing and asset disposal limits up to Rs. 50 crores offer greater financial flexibility but do not represent immediate debt or asset changes. The adjourned financial results prevent immediate assessment of profitability.
⚙️
Operational Impact
Relocating the registered office may necessitate administrative and legal adjustments. The enhanced limits empower the board for future operational financing and asset management decisions.
⚠️
Risk Impact
The shift requires shareholder and regulatory approvals, introducing execution risk. The increased financial limits introduce a risk of over-leveraging if not managed prudently.
👥 What This Means For Shareholders
✅
Action Required
Shareholders will need to vote on the proposed shift of the registered office and the enhancement of borrowing and asset limits.
👤
Who Is Affected
All shareholders are affected as they will be required to approve significant corporate actions impacting governance and financial capacity.
🔍
Management Signal
The management signals intent to increase operational flexibility and potentially expand the business through enhanced financial and asset management powers.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Shareholder meeting notice for approval of office shift and enhanced limits.
Intimation on completion of registered office shift to Maharashtra.
Outcome of adjourned Board Meeting for Q2 FY27 financial results.
MEDIUM RISK Key decisions are subject to external approvals (shareholder, regulatory), introducing uncertainty.
💡 Investor Takeaway
Parmax Pharma's board approved shifting its registered office to Maharashtra and enhancing borrowing/asset disposal limits to Rs. 50 crores each, pending shareholder consent. Financial results for Q2 FY27 were adjourned.
⚖️ Strengths & Concerns

✅ Positives

  • Approved enhancing limits for asset sale/mortgage to Rs. 50 crores, subject to shareholder approval.
  • Approved increasing borrowing limits to Rs. 50 crores, subject to shareholder approval.

⚠️ Concerns

  • Consideration of un-audited financial results for Q2 FY27 was adjourned, delaying financial updates.
  • Registered office shift and limit enhancements are subject to shareholder and regulatory approvals.
❓ Frequently Asked Questions
What key decisions were made by Parmax Pharma's Board on November 14, 2026?
The Board approved shifting the registered office to Maharashtra and enhancing borrowing and asset limits to Rs. 50 crores each.
Are the financial results for Parmax Pharma announced for the quarter ended September 30, 2026?
No, the consideration of un-audited financial results for the quarter and half-year ended September 30, 2026, was adjourned.
What is the new limit for borrowing approved by Parmax Pharma's Board?
The Board approved enhancing the borrowing limits up to Rs. 50 crores (Rupees Fifty Crores only), subject to shareholder approval.
Does Parmax Pharma plan to move its registered office?
Yes, the Board approved the proposal for shifting the Registered Office from Gujarat to Maharashtra, subject to shareholder and regulatory approvals.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.

Live IPO, GMP and market updates on Telegram

IPO open and close dates, grey market premium moves, subscription figures, allotment and listing days, and the market updates worth knowing about, posted on the channel as they happen.

Join the channel